

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/686,195	03/15/2004	Ralf Kollefrath	COLT 20.654 (101042-00006		
26304 7	590 05/03/2006		EXAMINER		
KATTEN MU	JCHIN ROSENMAN	STOKES, CANDICE CAPRI			
575 MADISO	N AVENUE				
NEW YORK, NY 10022-2585			ART UNIT	PAPER NUMBER	
,			3732		

DATE MAILED: 05/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

•			<i>J</i>
	Application No.	Applicant(s)	
·	10/686,195	KOLLEFRATH ET A	L.
Office Action Summary	Examiner	Art Unit	
	Candice C. Stokes	3732	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence addr	ess
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DOWN THE MAILING DOWN THE STATE OF THE MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this comi D (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 15 M	larch 2004.		
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.		
3) Since this application is in condition for allowa	nce except for formal matters, pro	secution as to the n	nerits is
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.	
Disposition of Claims			
4)⊠ Claim(s) <u>1-23</u> is/are pending in the application			
4a) Of the above claim(s) is/are withdra			
5)⊠ Claim(s) <u>21-23</u> is/are allowed.			
6)⊠ Claim(s) <u>1-8 and 14-18</u> is/are rejected.			
7)⊠ Claim(s) <u>9-13,19 and 20</u> is/are objected to.			
8) Claim(s) are subject to restriction and/o	r election requirement.		
Application Papers			
9)⊠ The specification is objected to by the Examine	or.		
10) ☐ The drawing(s) filed on 15 March 2004 is/are:		n by the Examiner	
Applicant may not request that any objection to the		7	
Replacement drawing sheet(s) including the correct			₹ 1 121(d)
11)☐ The oath or declaration is objected to by the Ex	· · · · · · · · · · · · · · · · · · ·	=	
Priority under 35 U.S.C. § 119			
12)⊠ Acknowledgment is made of a claim for foreign a)⊠ All b)□ Some * c)□ None of:	priority under 35 U.S.C. § 119(a	)-(d) or (f).	
1.⊠ Certified copies of the priority document	ts have been received.		
2. Certified copies of the priority document		on No	
3. Copies of the certified copies of the prior	rity documents have been receive	ed in this National S	tage
application from the International Burea	·		
* See the attached detailed Office action for a list	of the certified copies not receive	ed.	
Attachment(s)			
1) Notice of References Cited (PTO-892)	4) Interview Summary		
<ol> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> </ol>	Paper No(s)/Mail Di		152)
Paper No(s)/Mail Date <u>11/03;3/05;12/05</u> .	6) Other:		•

#### **DETAILED ACTION**

#### Abstract

The abstract of the disclosure is objected to because in line 1, "performing" should be "performing". Correction is required. See MPEP § 608.01(b).

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 1) Claims 1-3,5-7,14-15,17, and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Feinmann et al (USPN 4,677,139). The first portion of claim 1 is considered to be admitted prior art. Feinmann et al teaches a method for dentistry wherein a curable silicone material is applied to a wound in a patient's mouth, possibly following an extraction. The silicone material or elastomeric foam "being curable at body temperature and being capable of undergoing a volume of expansion of at least about 150% upon curing" (column 8, lines 17-20). This also anticipates claims 2-3 and 14-15. As to claim 5, the mold of elastomeric foam is capable of being held in place by the opposing row of teeth as shown in Fig. 9. Regarding claims 17 and 18, the curable molding mass comprises at least one additional silicone compound and a curing catalyst. Specifically, Feinmann et al teach "the elastomeric foam composition is formed from a system of components which includes silicone fluids, siliceous fillers,

Application/Control Number: 10/686,195

Art Unit: 3732

crosslinkers, hydrogen, sources and a catalyst" (see abstract). It would have been obvious to one having ordinary skill in the art at the time the invention was made to use a silicone material which is curable and expands when it cures in order to minimize substantial risk of postoperative tissue loss with aesthetically unsatisfying results" (column 1, lines 42-43).

2) Claims 4,8, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Feinmann et al in view of Dragan (USPN 6,890,177). Regarding claims 4,8, and 16, Feinmann et al teach the claimed invention in light of the admitted prior art except for at least one hemostatic agent being applied to the area between the tooth and gingival prior to the application of the silicone material. Dragan teaches a method and device for effecting the cordless retraction of the gingival sulcus wherein "to control any excessive gingival bleeding, an application of a liquid hemostatic agent 22, e.g. aluminum chloride, ferric sulfate or other suitable astringent is applied to the cut tissue in the area of the gingival sulcus" (column 3, lines 49-53). It would have been obvious to one having ordinary skill in the art at the time the ivnetion was made to incorporate the application of the hemostatic agent as taught by Dragan into the method with the silicone material as taught by Feinmann et al in order to provide a means for controlling the bleeding at the wound area prior to retracting the sulcus.

## Allowable Subject Matter

Claims 9-13 and 19-20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 21-23 are allowed.

Page 4

Application/Control Number: 10/686,195

Art Unit: 3732

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Candice C. Stokes whose telephone number is (571) 272-4714. The examiner can normally be reached on 8:00am - 4:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Shaver can be reached on (571) 272-4720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Candice C. Stokes

Cary E. O'Connor Primary Examiner